Anti-Cholesterol Medication Bombs In Tests Shares of Merck & Co.

Anti-Cholesterol Medication Bombs In Tests Shares of Merck & Co. And Schering-Plough Corp. Fell Mon after study results showed their combination cholesterol medication Vytorin worked zero better at reducing artery-clogging plaque in several high-risk patients than high doses of generic Zocor. The delayed Enhance study results had been anticipated with caution by Wall Street, with analysts stating data on both basic safety and effectiveness have the potential to influence future sales. While Vytorin reduced levels of ‘bad’ cholesterol much more than Zocor in the analysis and was been shown to be safe and well-tolerated, it failed to lower the amount of artery-clogging plaque ultimately.Preeclampsia is certainly a leading reason behind preterm birth and maternal/fetal death, arising in 5-8 percent of pregnant moms and characterized by high blood pressure and proteins in the urine after week 20 of being pregnant. Related StoriesPresence of connexin proteins suppresses principal tumor growthStudy reveals system behind protein-related diseasesDiscovery can offer clues to how some infections control expression of genetic material The technology was discovered by Carmenta's co-founders, Dr.

Other Posts From "laboratory":

Related Posts